NASDAQ:IDXX - IDEXX Laboratories Stock Price, Price Target & More

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories announced that its Board of Directors has authorized a stock buyback plan on Sunday, June 4th 2017, which permits the company to buyback 3,000,000 shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company's leadership believes its shares are undervalued.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings results on Friday, May, 4th. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.09. The business had revenue of $537.60 million for the quarter, compared to analyst estimates of $525.14 million. IDEXX Laboratories had a net margin of 13.87% and a negative return on equity of 530.24%. The business's revenue was up 16.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.77 earnings per share. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories issued an update on its FY18 earnings guidance on Friday, May, 4th. The company provided earnings per share guidance of $4.06-4.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.11. The company issued revenue guidance of +12-14% to ~$2.205-2.245 billion, compared to the consensus revenue estimate of $2.22 billion.

7 analysts have issued 12 month price objectives for IDEXX Laboratories' stock. Their predictions range from $200.00 to $260.00. On average, they expect IDEXX Laboratories' share price to reach $222.8333 in the next twelve months. This suggests that the stock has a possible downside of 7.1%. View Analyst Ratings for IDEXX Laboratories.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to IDEXX Laboratories include IPSEN S A/S (IPSEY), Immunomedics (IMMU), Neogen (NEOG), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT) and Vermillion (VRML).

News coverage about IDXX stock has been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. IDEXX Laboratories earned a news impact score of 0.18 on Accern's scale. They also gave news stories about the company an impact score of 44.78 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

IDEXX Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include American Capital Management Inc. (0.57%), Welch & Forbes LLC (0.21%), Bank of Montreal Can (0.19%), Franklin Street Advisors Inc. NC (0.06%), Spence Asset Management (0.06%) and Retirement Systems of Alabama (0.05%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including American Capital Management Inc., Calamos Advisors LLC, CenturyLink Investment Management Co, Welch & Forbes LLC, Spence Asset Management, Carderock Capital Management Inc., Retirement Systems of Alabama and Bath Savings Trust Co. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Rebecca M Henderson and William T End. View Insider Buying and Selling for IDEXX Laboratories.

IDXX stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Franklin Street Advisors Inc. NC, First Citizens Bank & Trust Co., State of Alaska Department of Revenue, V Wealth Management LLC, NN Investment Partners Holdings N.V., TRUE Private Wealth Advisors and Winslow Evans & Crocker Inc.. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IDXX stock can currently be purchased for approximately $239.79.

IDEXX Laboratories has a market capitalization of $20.69 billion and generates $1.97 billion in revenue each year. The company earns $263.14 million in net income (profit) each year or $3.28 on an earnings per share basis. IDEXX Laboratories employs 7,600 workers across the globe.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]